Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James J Marriott

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Journal of Central Nervous System Disease|July 18, 2013
Safety and efficacy of fingolimod in treatment-naïve multiple sclerosis patientsJames J Marriott
Multiple Sclerosis and Related Disorders|April 17, 2015
Thrombotic microangiopathy in Interferon Beta treated multiple sclerosis patients: Review of literature and report of two new casesReza Vosoughi, James J Marriott
Neurology|March 15, 2019
Patient-perceived risks of MS DMTs: Problems of communication and risk management?Gavin V McDonnell, James J Marriott
Neurologic Clinics|March 29, 2011
Definitions of breakthrough disease and second-line agentsJames J Marriott, Paul W O'Connor
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 4, 2010
Lessons learned from long-term multiple sclerosis treatment trialsJames J Marriott, Paul W O'Connor
Reviews on Recent Clinical Trials|May 27, 2010
Emerging therapies in relapsing-remitting multiple sclerosisJames J Marriott, Paul W O'Connor
Frontiers in Neurology|November 19, 2021
Development and Internal Validation of a Disability Algorithm for Multiple Sclerosis in Administrative DataRuth Ann Marrie, Qier Tan, Okechukwu Ekuma, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 27, 2022
Development of an indicator of smoking status for people with multiple sclerosis in administrative dataRuth Ann Marrie, Qier Tan, Okechukwu Ekuma, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 12, 2026
Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapiesDalia L Rotstein, Sheliza Halani, Peter Vadas, et al.
Neurology|May 5, 2010
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyJames J Marriott, Janis M Miyasaki, Gary Gronseth, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Journal of Central Nervous System Disease|July 18, 2013
Safety and efficacy of fingolimod in treatment-naïve multiple sclerosis patientsJames J Marriott
Multiple Sclerosis and Related Disorders|April 17, 2015
Thrombotic microangiopathy in Interferon Beta treated multiple sclerosis patients: Review of literature and report of two new casesReza Vosoughi, James J Marriott
Neurology|March 15, 2019
Patient-perceived risks of MS DMTs: Problems of communication and risk management?Gavin V McDonnell, James J Marriott
Neurologic Clinics|March 29, 2011
Definitions of breakthrough disease and second-line agentsJames J Marriott, Paul W O'Connor
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 4, 2010
Lessons learned from long-term multiple sclerosis treatment trialsJames J Marriott, Paul W O'Connor
Reviews on Recent Clinical Trials|May 27, 2010
Emerging therapies in relapsing-remitting multiple sclerosisJames J Marriott, Paul W O'Connor
Frontiers in Neurology|November 19, 2021
Development and Internal Validation of a Disability Algorithm for Multiple Sclerosis in Administrative DataRuth Ann Marrie, Qier Tan, Okechukwu Ekuma, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 27, 2022
Development of an indicator of smoking status for people with multiple sclerosis in administrative dataRuth Ann Marrie, Qier Tan, Okechukwu Ekuma, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 12, 2026
Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapiesDalia L Rotstein, Sheliza Halani, Peter Vadas, et al.
Neurology|May 5, 2010
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyJames J Marriott, Janis M Miyasaki, Gary Gronseth, et al.
Pageof 5